Genscript Biotech Corporation
金斯瑞生物科技股份有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

VOLUNTARY ANNOUNCEMENT
RESEARCH AND DEVELOPMENT UPDATE

Reference is made to the voluntary announcements of Genscript Biotech Corporation (the "**Company**", together with its subsidiaries, the "**Group**") dated 28 October 2016, 14 May 2017, 6 June 2017, 19 September 2017, 1 November 2018 and 4 December 2018. The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the European Medicines Agency ("**EMA**") granted a "PRIority MEdicines" ("**PRIME**") designation to Janssen-Cilag International N.V. ("**Janssen**") for JNJ-68284528 ("**JNJ-4528**"), the investigational B cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy, which has been previously identified as LCAR-B38M.

The PRIME scheme focuses on medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options. It offers companies enhanced interaction and early dialogue to optimize development plans and speed up the evaluation so that medicines can reach patients earlier. In order to be accepted for PRIME designation, a medicine must show its potential to benefit patients with unmet medical needs based on early clinical data.

In December 2017, (i) Legend Biotech USA Inc., a non-wholly-owned subsidiary of the Company ("**Legend U.S.**"), (ii) Legend Biotech Ireland Limited, a non-wholly-owned subsidiary of the Company ("**Legend Ireland**", together with Legend U.S., "**Legend**"), and (iii) Janssen Biotech, Inc. entered into the collaboration and license agreement to jointly develop and commercialize LCAR-B38M (JNJ-4528) in multiple myeloma. JNJ-4528 identifies the investigational product being studied in the United States or countries within the European Union and LCAR-B38M identifies the investigational product in China.

The PRIME designation is based on results from the Phase 1/2 LEGEND-2 study (NCT03090659) evaluating LCAR-B38M sponsored by Nanjing Legend Biotechnology Co., Ltd.* 南京傳奇生物科技有限公司, a controlled subsidiary of the Company as of the date of this announcement, and the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating JNJ-4528, sponsored by Janssen and being conducted in collaboration with Legend U.S.. Results from the LEGEND-2 study were presented at American Society of Clinical Oncology ("**ASCO**"), European Hematology Association and American Society of Hematology ("**ASH**") in 2017, and most recently at ASH 2018. It is anticipated that results from the CARTITUDE-1 study will be presented at a future congress.

In the United States or countries within the European Union, JNJ-4528 is currently being investigated in the CARTITUDE-1 study for the treatment of patients with multiple myeloma who have received at least three prior regimens, including a proteasome inhibitor ("**PI**"), an immunomodulatory drug ("**IMiD**"), and an anti-CD38 antibody, and have documented disease progression within 12 months of starting the most recent therapy, or are double refractory to an IMiD and PI. In China, the Phase 2 CARTIFAN-1 confirmatory trial (NCT03758417) registered with the Center for Drug Evaluation (CTR20181007), is actively recruiting to further evaluate LCAR-B38M in patients with advanced relapsed or refractory multiple myeloma.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 4 April 2019

As of the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Mr. Pan Jiuan.

* *For identification purposes only*